Drugs Made In America Acquisition Corp.
DMAADrugs Made In America Acquisition Corp. is a blank check company, also known as a special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, share exchange, or similar business combination.
Competitors
By market cap
Profile
Drugs Made In America Acquisition Corp. is a blank check company, also known as a special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, share exchange, or similar business combination. The company focuses on identifying and acquiring high-growth businesses within the artificial intelligence, pharmaceutical, and technology sectors that demonstrate a need for rapid innovation. Its primary value proposition is providing a target entity with a public listing and capital to accelerate growth and operational expansion.
The company is a shell entity with nominal assets and no operating history, competing with numerous other SPACs and private equity firms for high-quality acquisition targets.
FAQ
- What is Drugs Made In America Acquisition Corp.'s market cap?
- Drugs Made In America Acquisition Corp. (DMAA) has a market capitalization of $261.2M and trades on NASDAQ.
- Who are Drugs Made In America Acquisition Corp.'s competitors?
- Drugs Made In America Acquisition Corp.'s key competitors include United Acquisition Corp. I, GP-Act III Acquisition Corp. Class A Ordinary Share, Range Capital Acquisition Corp. Ordinary Shares, and others. These companies compete in similar markets and product categories.
- Who does Drugs Made In America Acquisition Corp. partner with?
- Drugs Made In America Acquisition Corp.'s notable partners include Clear Street LLC, BV Advisory Partners, LLC, Wilmington Trust, National Association, and others.
- Where is Drugs Made In America Acquisition Corp. headquartered?
- Drugs Made In America Acquisition Corp. is headquartered in United States of America. It has been publicly traded since 2025.